Menu
Menu
El GENOMiCS INSIGHTS Day Bogotá se llevará a cabo el próximo 23 de abril, en el Hotel W Bogotá.
Este encuentro reunirá a expertos, líderes clínicos y profesionales del área de la genómica para explorar los avances más recientes en medicina de precisión y el impacto creciente de las tecnologías genómicas en la práctica clínica.
Durante la jornada abordaremos temas clave como la visión global de innovación de SOPHiA GENETICS, las nuevas posibilidades clínicas de la biopsia líquida, experiencias reales de implementación en la práctica clínica con la plataforma SOPHiA DDM™, y nuevas oportunidades para ampliar el análisis genómico mediante exomas optimizados.
Este espacio también busca fomentar el intercambio de experiencias y la conversación entre profesionales del sector, promoviendo el avance de la medicina genómica en la región.
A continuación, encontrará la agenda preliminar del evento.
16:00 – 16:30
De la innovación al impacto: la visión global de SOPHiA GENETICS.
Ross Muken, President, SOPHiA GENETICS
16:30 – 17:00
Expandiendo las posibilidades clínicas con las soluciones de biopsia líquida de SOPHiA GENETICS.
Luna Rodriguez, Subject Matter Expert LATAM, SOPHiA GENETICS
17:00 - 17:30
Biopsia líquida en la práctica clínica: experiencia real con la plataforma SOPHiA DDM™.
July Katherine Rodriguez Ariza, Directora científica, FICMAC
17:30 – 18:00
Exomas optimizados: una nueva oportunidad para expandir el análisis genómico.
Gabriela Acosta, Sales Executive, LATAM SOPHiA GENETICS
Discover how SOPHiA DDM™ enables accurate analysis across multiple disease areas – from oncology to inherited disorders
Discuss the future of research and healthcare institutions to harness NGS data for quick, robust, and actionable insights, guiding best decisions.
Connect with your peers and enjoy a networking environment with your peers and users of SOPHiA DDM™ Platform
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
